At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
TG-0054 (2.24 mg/kg) +1 moredrug
Likely dose
TG-0054 (2.24 mg/kg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
In Brief
A Phase 2 clinical trial evaluating TG-0054 (2.24 mg/kg) and TG-0054 (3.14 mg/kg) for Multiple Myeloma and 2 related conditions. Completed, enrolled 19 participants across 6 sites.
Detailed Summary
A phase II study to evaluate the safety, pharmacokinetics, and hematopoietic stem cell mobilization of TG-0054 in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease
CountriesTaiwan
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2009
Enrollment StartFeb 2010
Primary CompletionOct 2011
TodayJul 2026
First PostedNov 25, 2009
Enrollment StartFeb 1, 2010
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 16.6 years ago
Interventions
TG-0054 (2.24 mg/kg)drug
TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
TG-0054 (3.14 mg/kg)drug
TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)